Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk
Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk
复制标题
DOI：
10.1046/j.1538-7836.2003.00279.x
复制
发表时间：
2003-07-01
影响因子：
10.4
通讯作者：
Morange, PE
中科院分区：
文献类型：
--
作者：
Juhan-Vague, I;Alessi, MC;Morange, PE
血浆纤溶酶原激活剂抑制剂-1 (PAI-1) 水平升高是胰岛素抵抗综合征 (IRS) 的核心特征。 IRS 中的动脉粥样硬化血栓并发症部分归因于血浆 PAI-1 水平升高引起的纤溶受损。尽管 IRS 的病因还远未得到解释，但炎症、脂肪组织积累和胰岛素抵抗的聚集表明了病因病理学上的联系。促炎细胞因子可能调节 IRS 中 PAI-1 的表达；然而。需要更多的研究来证实人类的这种复杂机制。此外，通过 PAI-1 抑制剂修饰 PAI-1 表达提供了新的挑战，并可能揭示 PAI-1 在动脉粥样硬化和胰岛素抵抗过程中的真正作用。
Elevated plasma plasminogen activator inhibitor-1 (PAI-1) level is a core feature of insulin-resistance syndrome (IRS). Atherothrombotic complications in IRS are partly attributed to impaired fibrinolysis caused by increased plasma PAI-1 levels. Although the etiology of IRS is far from being explained, the clustering of inflammation, adipose tissue accumulation and insulin resistance suggests an etiopathological link. Proinflammatory cytokines might regulate PAI-1 expression in IRS; however. more studies are needed to confirm this complex mechanism in humans. Furthermore, modifying PAI-1 expression by PAI-1 inhibitors provides a new challenge and may reveal the true role of PAI-1 in atherosclerotic and insulin resistance processes.